AI Summary of Scholarly Research

This page presents an AI-generated summary of a published research paper. The original authors did not write or review this article. [See full disclosure ↓]

Mandibular FUS::TFCP2-positive rhabdomyosarcoma resisted chemotherapy

Research area:medicine-clinicaloncology

What the study found

The case described an 11-year-old boy with a rare type of rhabdomyosarcoma, a cancer that forms in muscle tissue, in the mandible (jawbone). The tumor had a FUS::TFCP2 fusion gene, and it did not respond well to standard chemotherapy.

Why the authors say this matters

The authors conclude that early pathological diagnosis and prompt surgical intervention are crucial for FUS::TFCP2 fusion-positive rhabdomyosarcoma because the tumor is chemoresistant, meaning it resists conventional chemotherapy.

What the researchers tested

The researchers reported a single pediatric case of mandibular rhabdomyosarcoma. The child first received standard induction chemotherapy for rhabdomyosarcoma at a referring hospital, then underwent radical resection with segmental mandibulectomy and reconstruction using a rectus abdominis free flap.

What worked and what didn't

Standard induction chemotherapy was ineffective. After surgery, histological examination showed a viable tumor with minimal response to chemotherapy, and the patient remained disease-free for 18 months.

What to keep in mind

This is a single case report, so the findings are limited to one patient. The abstract does not describe broader treatment comparisons or an established optimal treatment strategy for this subtype.

Key points

  • The report describes an 11-year-old boy with mandibular rhabdomyosarcoma carrying a FUS::TFCP2 fusion gene.
  • Standard induction chemotherapy for rhabdomyosarcoma was ineffective in this case.
  • Radical surgery included segmental mandibulectomy and reconstruction with a rectus abdominis free flap.
  • Pathology after surgery showed a viable tumor with minimal chemotherapy response.
  • The patient remained disease-free for 18 months after surgery.

Disclosure

Research title:
Mandibular FUS::TFCP2-positive rhabdomyosarcoma resisted chemotherapy
Authors:
Kohtaro Eguchi, Eriko Uchida, Koichi Oshima, Kohei Fukuoka, Kayoko Tao, Ayumu Arakawa, Chihiro Fushimi, Go Omura, Taisuke Mori, Ai Yoshida, Katsuyoshi Koh, Seiichi Yoshimoto
Institutions:
National Cancer Center, National Cancer Center, National Cancer Center, National Cancer Center, National Cancer Center, National Cancer Center, National Cancer Center, National Cancer Center, National Cancer Center, Saitama Children's Medical Center, Saitama Children's Medical Center, Saitama Children's Medical Center
Publication date:
2026-03-09
OpenAlex record:
View
AI provenance: This post was generated by gpt-5.4-mini (OpenAI). The original authors did not write or review this post.